These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 18339074)

  • 21. Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin.
    Snoeck E; Wade JR; Duff F; Lamb M; Jorga K
    Br J Clin Pharmacol; 2006 Dec; 62(6):699-709. PubMed ID: 17118125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China.
    Zhao H; Kurbanov F; Wan MB; Yin YK; Niu JQ; Hou JL; Wei L; Wang GQ; Tanaka Y; Mizokami M; Si CW
    Clin Infect Dis; 2007 Feb; 44(4):541-8. PubMed ID: 17243057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan.
    Sullivan SD; Veenstra DL; Chen PJ; Chang TT; Chuang WL; Tsai C; Patel K
    J Gastroenterol Hepatol; 2007 Sep; 22(9):1494-9. PubMed ID: 17716353
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin.
    Rustgi VK; Esposito S; Hamzeh FM; Shiffman ML
    Aliment Pharmacol Ther; 2008 Mar; 27(5):433-40. PubMed ID: 18081737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B.
    Bonino F; Marcellin P; Lau GK; Hadziyannis S; Jin R; Piratvisuth T; Germanidis G; Yurdaydin C; Diago M; Gurel S; Lai MY; Brunetto MR; Farci P; Popescu M; McCloud P;
    Gut; 2007 May; 56(5):699-705. PubMed ID: 17127704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of peginterferon alpha-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom.
    Veenstra DL; Sullivan SD; Dusheiko GM; Jacobs M; Aledort JE; Lewis G; Patel KK
    Eur J Gastroenterol Hepatol; 2007 Aug; 19(8):631-8. PubMed ID: 17625431
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4.
    Hasan F; Asker H; Al-Khaldi J; Siddique I; Al-Ajmi M; Owaid S; Varghese R; Al-Nakib B
    Am J Gastroenterol; 2004 Sep; 99(9):1733-7. PubMed ID: 15330911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
    N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New and emerging treatment of chronic hepatitis B.
    Keeffe EB; Marcellin P
    Clin Gastroenterol Hepatol; 2007 Mar; 5(3):285-94. PubMed ID: 17218162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peginterferon alfa-2a (40KD) (Pegasys) for the treatment of patients with chronic hepatitis C.
    Ferenci P
    Int J Clin Pract; 2003 Sep; 57(7):610-5. PubMed ID: 14529063
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit.
    Covic A; Maftei ID; Mardare NG; Ioniţă-Radu F; Totolici C; Tuţă L; Golea O; Covic M; Volovăţ C; Gusbeth-Tatomir P; Mircescu G
    J Nephrol; 2006; 19(6):794-801. PubMed ID: 17173254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C.
    Reddy KR; Wright TL; Pockros PJ; Shiffman M; Everson G; Reindollar R; Fried MW; Purdum PP; Jensen D; Smith C; Lee WM; Boyer TD; Lin A; Pedder S; DePamphilis J
    Hepatology; 2001 Feb; 33(2):433-8. PubMed ID: 11172346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term efficacy of pegylated interferon alpha-2a in HCV-positive hemodialysis patients.
    Ucmak H; Kokoglu OF; Hosoglu S; Dogan E; Sayarlioglu H; Kuzhan N; Isik IO
    Ren Fail; 2008; 30(2):227-32. PubMed ID: 18300126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of Peginterferon alpha-2b (12 kDa) and Lamivudine in difficult-to-treat chronic hepatitis B- an Indian experience.
    Amarapurkar DN; Patel ND
    Ann Hepatol; 2005; 4(1):56-9. PubMed ID: 15798663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B.
    Musch E; Högemann B; Gerritzen A; Fischer HP; Wiese M; Kruis W; Malek M; Gugler R; Schmidt G; Huchzermeyer H; Gerlach U; Dengler HJ; Sauerbruch T
    Hepatogastroenterology; 1998; 45(24):2282-94. PubMed ID: 9951911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C.
    Hassanein T; Cooksley G; Sulkowski M; Smith C; Marinos G; Lai MY; Pastore G; Trejo-Estrada R; Horta E Vale A; Wintfeld N; Green J
    J Hepatol; 2004 Apr; 40(4):675-81. PubMed ID: 15030985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical study on adverse reactions of peginterferon alfa-2a in treatment of chronic hepatitis in adults and children].
    Tang HM; Zhang HF; Zhu SS; Zhang YP; Huo CH; Wang LM
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Oct; 22(5):370-2. PubMed ID: 19469178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biphasic pattern of depression and its predictors during pegylated interferon-based therapy in chronic hepatitis B and C patients.
    Huang YW; Hu JT; Hu FC; Chang CJ; Chang HY; Kao JH; Yang SS; Chen DS
    Antivir Ther; 2013; 18(4):567-73. PubMed ID: 23072880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial.
    Fartoux L; Degos F; Trépo C; Goria O; Calès P; Tran A; Buffet C; Poynard T; Capron D; Raabe JJ; Roulot D; Naveau S; Grange JD; Poupon RE; Poupon R; Serfaty L
    Clin Gastroenterol Hepatol; 2007 Apr; 5(4):502-7. PubMed ID: 17261383
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reversible bilateral ototoxicity in a patient with chronic hepatitis B during peginterferon alpha-2a treatment.
    Gozdas HT; Karabay O
    Indian J Pharmacol; 2015; 47(1):121-2. PubMed ID: 25821325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.